HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other - PubMed (original) (raw)
HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other
P J Goulder et al. J Virol. 2000 Jun.
Abstract
Viral peptides are recognized by cytotoxic T lymphocytes (CTL) as a complex with major histocompatibility complex (MHC) class I molecules, but the extent to which a single HLA allele can accommodate epitope peptides of different length and sequence is not well characterized. Here we report the identification of clonal CTL responses from the same donor that independently recognize one of two HLA-B57-restricted epitopes, KAFSPEVIPMF (KF11; p24(Gag) residues 30 to 40) and KAFSPEVI (KF8; p24(Gag) residues 30 to 37). Although lysis studies indicated that the KF11 peptide stabilized the HLA-B57-peptide complex more efficiently than the KI8 peptide, strong clonal responses were directed at each epitope. In samples from a second donor, the same phenomenon was observed, in which distinct CTL clones recognized peptide epitopes presented by the same HLA class I allele (in this case, HLA-A3) which were entirely overlapping. These data are relevant to the accurate characterization of CTL responses, which is fundamental to a detailed understanding of MHC class I-restricted immunity. In addition, these studies demonstrate marked differences in the length of peptides presented by HLA-B57, an allele which is associated with nonprogressive human immunodeficiency virus infection.
Figures
FIG. 1
(A) Patterns of recognition of peptides KI13 (KVIEEKAFSPEVI) and KF11 (KAFSPEVIPMF) by six representative CTL clones derived from donor 026-BMC. The peptide concentration was 100 μM, the effector-target cell (E:T) ratio in each case was 5:1, and the target cells were autologous EBV-transformed B cells (B-LCL). (B) Pattern of recognition of the same peptides by the same CTL clones as in panel A but using HLA-B57-matched targets from donor 003-BMC (HLA class I type of target cells, A23/—B45/57 Cw6/16; HLA class I type of 026-BMC CTL clones, A3/—B42/57 Cw7/17). The peptide concentration used was 10 μM, and the E:T ratio was 5:1. There was no recognition of target cells matched through class I molecules other than B57 or of HLA-mismatched targets (data not shown).
FIG. 2
(A) Recognition of truncations of IK13 (KVIEEKAFSPEVI) and KF11 (KAFSPEVIPMF) by four representative CTL clones. The peptide concentration was 10 μM, the targets were B57-matched B-LCL from donor 003-BMC, and the E:T ratio was 5:1. (B) Recognition of truncations of KF11 at concentrations of peptide of 1, 10, and 100 μM by CTL clone 1 (similar pattern of recognition was observed for clone 2; not shown). Target cells were the same as in panel A. (C) Recognition of peptides differing by one amino acid at the N-terminal and C-terminal residues from the optimal peptide KI8 (KAFSPEVI) recognized by CTL clone 4 (a similar pattern of recognition was observed for clone 5; not shown) using concentrations of peptide of 1, 10, and 100 μM. Target cells were as in panel A. (D) Peptide titration curves showing specific recognition of KF11 by clone 1 and specific recognition of KI8 by clone 4. Target cells were as in panel A.
FIG. 2
(A) Recognition of truncations of IK13 (KVIEEKAFSPEVI) and KF11 (KAFSPEVIPMF) by four representative CTL clones. The peptide concentration was 10 μM, the targets were B57-matched B-LCL from donor 003-BMC, and the E:T ratio was 5:1. (B) Recognition of truncations of KF11 at concentrations of peptide of 1, 10, and 100 μM by CTL clone 1 (similar pattern of recognition was observed for clone 2; not shown). Target cells were the same as in panel A. (C) Recognition of peptides differing by one amino acid at the N-terminal and C-terminal residues from the optimal peptide KI8 (KAFSPEVI) recognized by CTL clone 4 (a similar pattern of recognition was observed for clone 5; not shown) using concentrations of peptide of 1, 10, and 100 μM. Target cells were as in panel A. (D) Peptide titration curves showing specific recognition of KF11 by clone 1 and specific recognition of KI8 by clone 4. Target cells were as in panel A.
FIG. 3
(A) Stabilization of peptide-B57 complexes by the peptides KF11 and KI8. Clone 1 (specific for KF11) shows recognition of KF11-pulsed targets >75 h after peptide pulsing. Clone 4 (specific for KI8) showed recognition of KI8-pulsed target cells for <18 h after peptide pulsing. The peptide concentration used was 10 μM. Targets and E:T ratios were as in Fig. 2. (B) Frequency of peptide-specific responses by Elispot assay following epitope optimization using fresh PBMC. The peptide concentration was 10 μM. Error bars show SD from the mean of four replicates for each peptide shown.
FIG. 4
(A) Recognition of previously defined HLA-A3-restricted CTL epitopes RLRPGGKKK (RK9) and RLRPGGKKKY (RY10) by four clones derived from PBMC from donor 021-BMC (HLA A3/3001 B42/—Cw17/—). Targets were B-LCL from donor KS (HLA class I type A3/— B7/— Cw7/—) at an E:T ratio of 5:1. Specific lysis by the clones of targets pulsed with the peptide KIRLRPGGK (KK9) was between −1 and 0% (not shown). (B) Fine specificity of CTL clone 1. The best-recognized peptide was RY10. Similar data using CTL from clone 2 are not shown. Targets were the same as in panel A. (C) Fine specificity of CTL clone 3. The best-recognized peptide was RLRPGGKKKYK (RK11). Similar data using CTL from clone 4 are not shown. Targets were the same as in panel A.
FIG. 4
(A) Recognition of previously defined HLA-A3-restricted CTL epitopes RLRPGGKKK (RK9) and RLRPGGKKKY (RY10) by four clones derived from PBMC from donor 021-BMC (HLA A3/3001 B42/—Cw17/—). Targets were B-LCL from donor KS (HLA class I type A3/— B7/— Cw7/—) at an E:T ratio of 5:1. Specific lysis by the clones of targets pulsed with the peptide KIRLRPGGK (KK9) was between −1 and 0% (not shown). (B) Fine specificity of CTL clone 1. The best-recognized peptide was RY10. Similar data using CTL from clone 2 are not shown. Targets were the same as in panel A. (C) Fine specificity of CTL clone 3. The best-recognized peptide was RLRPGGKKKYK (RK11). Similar data using CTL from clone 4 are not shown. Targets were the same as in panel A.
Similar articles
- Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53.
Dorrell L, Willcox BE, Jones EY, Gillespie G, Njai H, Sabally S, Jaye A, DeGleria K, Rostron T, Lepin E, McMichael A, Whittle H, Rowland-Jones S. Dorrell L, et al. Eur J Immunol. 2001 Jun;31(6):1747-56. doi: 10.1002/1521-4141(200106)31:6<1747::aid-immu1747>3.0.co;2-l. Eur J Immunol. 2001. PMID: 11385619 - Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses.
Klein MR, van der Burg SH, Hovenkamp E, Holwerda AM, Drijfhout JW, Melief CJ, Miedema F. Klein MR, et al. J Gen Virol. 1998 Sep;79 ( Pt 9):2191-201. doi: 10.1099/0022-1317-79-9-2191. J Gen Virol. 1998. PMID: 9747728 - Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay.
Altfeld MA, Trocha A, Eldridge RL, Rosenberg ES, Phillips MN, Addo MM, Sekaly RP, Kalams SA, Burchett SA, McIntosh K, Walker BD, Goulder PJ. Altfeld MA, et al. J Virol. 2000 Sep;74(18):8541-9. doi: 10.1128/jvi.74.18.8541-8549.2000. J Virol. 2000. PMID: 10954555 Free PMC article. - Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.
Goulder PJ, Brander C, Annamalai K, Mngqundaniso N, Govender U, Tang Y, He S, Hartman KE, O'Callaghan CA, Ogg GS, Altfeld MA, Rosenberg ES, Cao H, Kalams SA, Hammond M, Bunce M, Pelton SI, Burchett SA, McIntosh K, Coovadia HM, Walker BD. Goulder PJ, et al. J Virol. 2000 Jun;74(12):5679-90. doi: 10.1128/jvi.74.12.5679-5690.2000. J Virol. 2000. PMID: 10823876 Free PMC article. - Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa.
Masemola AM, Mashishi TN, Khoury G, Bredell H, Paximadis M, Mathebula T, Barkhan D, Puren A, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, Karim SA, Sheppard HW, Gray CM; HIVNET 028 Study Team. Masemola AM, et al. J Immunol. 2004 Oct 1;173(7):4607-17. doi: 10.4049/jimmunol.173.7.4607. J Immunol. 2004. PMID: 15383595
Cited by
- Epitope length variants balance protective immune responses and viral escape in HIV-1 infection.
Pymm P, Tenzer S, Wee E, Weimershaus M, Burgevin A, Kollnberger S, Gerstoft J, Josephs TM, Ladell K, McLaren JE, Appay V, Price DA, Fugger L, Bell JI, Schild H, van Endert P, Harkiolaki M, Iversen AKN. Pymm P, et al. Cell Rep. 2022 Mar 1;38(9):110449. doi: 10.1016/j.celrep.2022.110449. Cell Rep. 2022. PMID: 35235807 Free PMC article. - In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction.
Silva-Arrieta S, Goulder PJR, Brander C. Silva-Arrieta S, et al. PLoS Pathog. 2020 Jun 4;16(6):e1008607. doi: 10.1371/journal.ppat.1008607. eCollection 2020 Jun. PLoS Pathog. 2020. PMID: 32497149 Free PMC article. No abstract available. - Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide.
Barquera R, Collen E, Di D, Buhler S, Teixeira J, Llamas B, Nunes JM, Sanchez-Mazas A. Barquera R, et al. HLA. 2020 Sep;96(3):277-298. doi: 10.1111/tan.13956. Epub 2020 Jun 11. HLA. 2020. PMID: 32475052 Free PMC article. - Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability.
Moynihan KD, Holden RL, Mehta NK, Wang C, Karver MR, Dinter J, Liang S, Abraham W, Melo MB, Zhang AQ, Li N, Gall SL, Pentelute BL, Irvine DJ. Moynihan KD, et al. Cancer Immunol Res. 2018 Sep;6(9):1025-1038. doi: 10.1158/2326-6066.CIR-17-0607. Epub 2018 Jun 18. Cancer Immunol Res. 2018. PMID: 29915023 Free PMC article. - Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection.
Adland E, Hill M, Lavandier N, Csala A, Edwards A, Chen F, Radkowski M, Kowalska JD, Paraskevis D, Hatzakis A, Valenzuela-Ponce H, Pfafferott K, Williams I, Pellegrino P, Borrow P, Mori M, Rockstroh J, Prado JG, Mothe B, Dalmau J, Martinez-Picado J, Tudor-Williams G, Frater J, Stryhn A, Buus S, Teran GR, Mallal S, John M, Buchbinder S, Kirk G, Martin J, Michael N, Fellay J, Deeks S, Walker B, Avila-Rios S, Cole D, Brander C, Carrington M, Goulder P. Adland E, et al. J Virol. 2018 Jan 30;92(4):e01685-17. doi: 10.1128/JVI.01685-17. Print 2018 Feb 15. J Virol. 2018. PMID: 29167337 Free PMC article.
References
- Allen T M, Sidney J, del Guerico M F, Glickman R L, Lensmeye G L, Wiebe D A, DeMars R, Pauza C D, Johnson R P, Sette A, Watkins D I. Characterization of the peptide-binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from SIV. J Immunol. 1998;160:6062–6071. - PubMed
- Altman J, Moss P A H, Goulder P J R, Barouch D H, McHeyzer-Williams M G, Bell J I, McMichael A J, Davis M M. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. Science. 1996;274:94–96. - PubMed
- Androlewicz M J, Cresswell P. How selective is the transporter associated with antigen processing? Immunity. 1996;5:1–5. - PubMed
- Barber L D, Percival L, Arnett K L, Gumperz J E, Chen L, Parham P. Polymorphism in the a1 helix of the HLA-B heavy chain can have an overriding influence on peptide-binding specificity. J Immunol. 1997;158:1660–1669. - PubMed
- Brander C, Walker B D. The HLA class I restricted CTL response in HIV infection: systematic identification of optimal epitopes. In: Korber B T M, Brander C, Walker B D, Koup R A, Moore J, Haynes B, Meyers G, editors. HIV molecular immunology database. Los Alamos, N. Mex: Los Alamos National Laboratory; 1998.
Publication types
MeSH terms
Substances
Grants and funding
- AI30914/AI/NIAID NIH HHS/United States
- R37 AI028568/AI/NIAID NIH HHS/United States
- AI28568/AI/NIAID NIH HHS/United States
- R01 AI028568/AI/NIAID NIH HHS/United States
- R01 AI030914/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials